مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
LibKey Link

مصطلحات الفهرس: drug blood level, drug dose escalation, drug safety, drug tolerability, human, maximum tolerated dose, phase 1 clinical trial, phase 2 clinical trial, priority journal, solid malignant neoplasm/dt [Drug Therapy], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/cm [Drug Comparison], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/pd [Pharmacology], cyclodextrin, docetaxel/dt [Drug Therapy], macrogol, nanoparticle, antineoplastic agent/cr [Drug Concentration], antineoplastic activity, article, advanced cancer, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39641Test
Annals of Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145Test
Journal for ImmunoTherapy of Cancer
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375Test
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug blood level, drug dose escalation, drug safety, drug tolerability, human, maximum tolerated dose, phase 1 clinical trial, phase 2 clinical trial, priority journal, solid malignant neoplasm/dt [Drug Therapy], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/cm [Drug Comparison], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/pd [Pharmacology], cyclodextrin, docetaxel/dt [Drug Therapy], macrogol, nanoparticle, antineoplastic agent/cr [Drug Concentration], antineoplastic activity, article, advanced cancer, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39641Test
Annals of Oncology
LibKey Link

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145Test
Journal for ImmunoTherapy of Cancer
LibKey Link

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375Test
Australasian Journal of Dermatology
LibKey Link

مصطلحات الفهرس: drug efficacy, drug potentiation, encephalitis/si [Side Effect], fatigue/si [Side Effect], genetic heterogeneity, genomics, hand foot syndrome/si [Side Effect], hedgehog signaling, human, hypertension/si [Side Effect], liquid biopsy, monotherapy, mutational load, nonhuman, Notch signaling, overall survival, pneumonia/si [Side Effect], progression free survival, review, small cell lung cancer/dt [Drug Therapy], small cell lung cancer/rt [Radiotherapy], solid malignant neoplasm/dt [Drug Therapy], adavosertib/ct [Clinical Trial], adavosertib/cb [Drug Combination], adavosertib/dt [Drug Therapy], alisertib/ct [Clinical Trial], alisertib/cb [Drug Combination], alisertib/cm [Drug Comparison], alisertib/dt [Drug Therapy], anlotinib/ae [Adverse Drug Reaction], anlotinib/ct [Clinical Trial], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cediranib/ct [Clinical Trial], cediranib/cb [Drug Combination], cediranib/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cixutumumab/cb [Drug Combination], cixutumumab/dt [Drug Therapy], crlx101/ct [Clinical Trial], crlx101/cb [Drug Combination], crlx101/dt [Drug Therapy], durvalumab/ct [Clinical Trial], durvalumab/cb [Drug Combination], durvalumab/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/ct [Clinical Trial], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], gemcitabine/ct [Clinical Trial], gemcitabine/cb [Drug Combination], gemcitabine/dt [Drug Therapy], ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/cm [Drug Comparison], ipilimumab/dt [Drug Therapy], lurbinectedin/ae [Adverse Drug Reaction], lurbinectedin/ct [Clinical Trial], lurbinectedin/dt [Drug Therapy], lurbinectedin/tm [Unexpected Outcome of Drug Treatment], niraparib/ct [Clinical Trial], niraparib/cb [Drug Combination], niraparib/cm [Drug Comparison], niraparib/dt [Drug Therapy], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/cb [Drug Combination], nivolumab/cm [Drug Comparison], nivolumab/dt [Drug Therapy], olaparib/ae [Adverse Drug Reaction], olaparib/ct [Clinical Trial], olaparib/cb [Drug Combination], olaparib/cm [Drug Comparison], olaparib/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], placebo, prexasertib/ct [Clinical Trial], prexasertib/cb [Drug Combination], prexasertib/dt [Drug Therapy], rovalpituzumab tesirine/ct [Clinical Trial], rovalpituzumab tesirine/cb [Drug Combination], rovalpituzumab tesirine/cm [Drug Comparison], rovalpituzumab tesirine/dt [Drug Therapy], rucaparib/ct [Clinical Trial], rucaparib/cb [Drug Combination], rucaparib/dt [Drug Therapy], sonidegib/ct [Clinical Trial], sonidegib/cb [Drug Combination], sonidegib/dt [Drug Therapy], sonidegib/tm [Unexpected Outcome of Drug Treatment], taladegib/ct [Clinical Trial], taladegib/cb [Drug Combination], taladegib/dt [Drug Therapy], talazoparib/dt [Drug Therapy], talazoparib/tm [Unexpected Outcome of Drug Treatment], temozolomide/ae [Adverse Drug Reaction], temozolomide/ct [Clinical Trial], temozolomide/cb [Drug Combination], temozolomide/dt [Drug Therapy], topotecan/ct [Clinical Trial], topotecan/cm [Drug Comparison], topotecan/dt [Drug Therapy], unindexed drug, veliparib/ae [Adverse Drug Reaction], veliparib/ct [Clinical Trial], veliparib/cb [Drug Combination], veliparib/cm [Drug Comparison], veliparib/dt [Drug Therapy], vismodegib/dt [Drug Therapy], vismodegib/cb [Drug Combination], anlotinib/cm [Drug Comparison], anlotinib/dt [Drug Therapy], bevacizumab/ct [Clinical Trial], bevacizumab/cb [Drug Combination], bevacizumab/dt [Drug Therapy], adoptive immunotherapy, anorexia/si [Side Effect], blood toxicity/si [Side Effect], bone marrow suppression/si [Side Effect], cancer immunotherapy, cancer resistance, circulating tumor cell, DNA damage response, drug dose escalation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35889Test
Cancers
Click here for full text options
LibKey Link

مصطلحات الفهرس: clinical article, antineoplastic activity, arthralgia/si [Side Effect], article, autoimmune hepatitis/dt [Drug Therapy], autoimmune hepatitis/si [Side Effect], backache/si [Side Effect], cohort analysis, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dose escalation, drug dose reduction, drug safety, drug tolerability, drug withdrawal, dysgeusia/si [Side Effect], fatigue/si [Side Effect], female, female genital tract cancer/dt [Drug Therapy], fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], headache/si [Side Effect], hepatitis/si [Side Effect], human, hypothyroidism/si [Side Effect], immunopathology/si [Side Effect], infusion related reaction/si [Side Effect], kidney dysfunction/si [Side Effect], life expectancy, limb pain/si [Side Effect], maculopapular rash/si [Side Effect], male, maximum tolerated dose, multicenter study, nausea/si [Side Effect], open study, phase 1 clinical trial, priority journal, pruritus/si [Side Effect], rash/si [Side Effect], side effect/si [Side Effect], single drug dose, small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], gamma glutamyltransferase/ec [Endogenous Compound], pamiparib/ae [Adverse Drug Reaction], pamiparib/ct [Clinical Trial], pamiparib/cb [Drug Combination], pamiparib/do [Drug Dose], pamiparib/dt [Drug Therapy], pamiparib/po [Oral Drug Administration], pamiparib/tm [Unexpected Outcome of Drug Treatment], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cb [Drug Combination], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/tm [Unexpected Outcome of Drug Treatment], abdominal pain/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, anemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35995Test
The Lancet Oncology
Click here for full text options
LibKey Link